Lineage Cell Therapeutics, Inc. SEC filings LCTX
Lineage Cell Therapeutics, Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Jul 3, 2012. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 6, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 29, 2026 | — |
| DEF 14A | Proxy statement | Apr 29, 2026 | Apr 29, 2026 |
| DEFA14A | Additional proxy material | Jun 11, 2025 | — |
| DEFA14A | Additional proxy material | Apr 29, 2025 | — |
| DEF 14A | Proxy statement | Apr 29, 2025 | Jun 26, 2025 |
| DEF 14A | Proxy statement | Dec 9, 2024 | Dec 9, 2024 |
| PRE 14A | Preliminary proxy statement | Nov 29, 2024 | Nov 29, 2024 |
| DEFA14A | Additional proxy material | Apr 29, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 11, 2024 |
| DEFA14A | Additional proxy material | Jul 27, 2023 | — |
| DEF 14A | Proxy statement | Jul 27, 2023 | Jul 27, 2023 |
| PRE 14A | Preliminary proxy statement | Jul 11, 2023 | Jul 11, 2023 |
| DEFA14A | Additional proxy material | Apr 29, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Apr 29, 2022 |
| DEFA14A | Additional proxy material | Sep 2, 2021 | — |
| DEFA14A | Additional proxy material | Aug 3, 2021 | — |
| DEF 14A | Proxy statement | Aug 3, 2021 | Aug 3, 2021 |
| DEF 14A | Proxy statement | Aug 7, 2020 | Aug 7, 2020 |
| DEFA14A | Additional proxy material | Aug 7, 2020 | — |
| DEFA14A | Additional proxy material | Jun 14, 2019 | — |
| DEF 14A | Proxy statement | Jun 14, 2019 | Jun 14, 2019 |
| DEFA14A | Additional proxy material | Mar 29, 2018 | — |
| DEF 14A | Proxy statement | Mar 29, 2018 | Mar 29, 2018 |
| PRE 14A | Preliminary proxy statement | Mar 19, 2018 | Mar 19, 2018 |
| DEFA14A | Additional proxy material | Jun 30, 2017 | — |
| DEFA14A | Additional proxy material | May 3, 2017 | — |
| DEF 14A | Proxy statement | May 1, 2017 | Apr 27, 2017 |
| DEFA14A | Additional proxy material | May 3, 2016 | — |
| DEF 14A | Proxy statement | Apr 29, 2016 | Jun 9, 2016 |
| PRE 14A | Preliminary proxy statement | Apr 15, 2016 | Jun 9, 2016 |
| DEFA14A | Additional proxy material | Jun 11, 2015 | — |
| DEF 14A | Proxy statement | Jun 11, 2015 | Jul 10, 2015 |
| DEFA14A | Additional proxy material | Oct 14, 2014 | — |
| DEF 14A | Proxy statement | Oct 14, 2014 | Nov 4, 2014 |
| DEFA14A | Additional proxy material | Oct 7, 2013 | — |
| DEF 14A | Proxy statement | Oct 7, 2013 | Oct 28, 2013 |
| DEF 14A | Proxy statement | Apr 22, 2013 | May 21, 2013 |
| DEFA14A | Additional proxy material | Mar 7, 2013 | — |
| PRE 14A | Preliminary proxy statement | Mar 5, 2013 | Mar 5, 2013 |
| DEFA14A | Additional proxy material | Jan 8, 2013 | — |
| DEFA14A | Additional proxy material | Jan 7, 2013 | — |
Showing 41 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- LCTX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- CA
- Headquarters
- Carlsbad, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 876343
- Former names
- BIOTIME INC (until Aug 8, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.